百信國際(00574.HK)全年虧損約1.93億元
格隆匯 6 月 23日丨百信國際(00574.HK)發佈公告,截至2019年12月31日止年度,收益約為人民幣8.45億元(單位下同),同比增長3%;年內虧損約1.93億元(2018年:約6340.8萬元);每股基本虧損13.38分;不建議派付末期股息。
報告期內,集團錄得總收益較去年增加約3.0%。有關增加主要由於集團向批發商及醫院以及農村地區的其他醫療機構作出的醫藥分銷所得收益增加所致。2019年,集團醫藥分銷分部產生收益約為人民幣7.985億元,較2018年增加約5.8%。集團醫藥分銷的收益增長來自批發商、醫院及農村地區的其他醫療機構。但由於中國實行兩票制後,醫藥分銷競爭加劇,2019年醫藥分銷的毛利率持續惡化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.